The ASTRAZENECa/Oxford University COVID-19 vaccine responds strongly: 100% of the subjects had neutralizing antibodies.

!---- The sars-CoV-2 vaccine, developed jointly by AstraZeneca and Oxford University, has a promising future in clinical trialsinterim data from the ongoing I/II COV001 trial, led by the University of Oxford, showed that AZD1222 was resistant and caused a strong immune response to COVID-19 in all subjectsphoto source: Results published in The Lancet confirmed a fourfold increase in the number of SARS-CoV-2 viral stingprotein antibodies in 95 percent of participants within a month of the injection of the single dose OF AZD1222in all participants, T-cell reactions were induced, peaking on the 14th day and maintained for two months after injectionneutralizing activity against SARS-CoV-2 was observed in 91% of participants and 100% of participants receiving a second dose one month after vaccinationin terms of safety, AZD1222 group of common transient local and systemic reactions, including temporary injection site pain and tenderness, mild to moderate headache, fatigue, chills, fever, general weakness and muscle sorenessnote, AZD1222 did not report serious adverse events, the use of preventive paracetamol to reduce the response, and the frequency of occurrence after the second administrationMene Pangalos, executive vice president ofAZ Bio Pharmaceuticals R and D, said the medium-term results of the trial were "encouraging""While more needs to be done, these data increase our confidence and allow us to continue our plans for mass production of vaccines for wide use worldwide,""